Neeraj Agarwal, Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), shared a post on X:
“Breaking news from ESMO25.
Improved OS in high risk biochemical recurrent Prostate Cancer on with ENZA+ADT vs ADT alone, HR: 0.59 (no OS benefit with ENZA monotherapy), wonderful news for our pts congrats Stephen Freedland, Neal Shore and the team.”
You Can Also Read:
ESMO 2025 Day 1 Highlights Not to Miss
ESMO 2025 Day 2 Highlights Not to Miss
